Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EBIT: 2010-2025

Historic EBIT for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $66.3 million.

  • Catalyst Pharmaceuticals' EBIT rose 30.17% to $66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.8 million, marking a year-over-year increase of 48.74%. This contributed to the annual value of $195.1 million for FY2024, which is 124.77% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported EBIT of $66.3 million as of Q3 2025, which was down 0.05% from $66.3 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' EBIT registered a high of $66.3 million during Q2 2025, and its lowest value of -$37.2 million during Q3 2023.
  • Over the past 3 years, Catalyst Pharmaceuticals' median EBIT value was $50.9 million (recorded in 2024), while the average stood at $43.4 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' EBIT plummeted by 248.15% in 2023 and then spiked by 236.90% in 2024.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' EBIT stood at $12.7 million in 2021, then soared by 141.73% to $30.8 million in 2022, then soared by 35.36% to $41.7 million in 2023, then spiked by 50.73% to $62.8 million in 2024, then skyrocketed by 30.17% to $66.3 million in 2025.
  • Its EBIT was $66.3 million in Q3 2025, compared to $66.3 million in Q2 2025 and $63.4 million in Q1 2025.